- Home
- MFIN vs AARD Comparison
MFIN vs AARD Comparison
Compare MFIN & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIN
- AARD
- Stock Information
- Founded
- MFIN 1995
- AARD 2017
- Country
- MFIN United States
- AARD United States
- Employees
- MFIN N/A
- AARD N/A
- Industry
- MFIN Finance: Consumer Services
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- MFIN Finance
- AARD Health Care
- Exchange
- MFIN Nasdaq
- AARD Nasdaq
- Market Cap
- MFIN 243.9M
- AARD 231.9M
- IPO Year
- MFIN 1996
- AARD 2025
- Fundamental
- Price
- MFIN $10.03
- AARD $9.64
- Analyst Decision
- MFIN Strong Buy
- AARD Strong Buy
- Analyst Count
- MFIN 1
- AARD 8
- Target Price
- MFIN $12.00
- AARD $30.63
- AVG Volume (30 Days)
- MFIN 44.9K
- AARD 151.4K
- Earning Date
- MFIN 10-29-2025
- AARD 11-13-2025
- Dividend Yield
- MFIN 4.81%
- AARD N/A
- EPS Growth
- MFIN 1.06
- AARD N/A
- EPS
- MFIN 1.71
- AARD N/A
- Revenue
- MFIN $338,783,000.00
- AARD N/A
- Revenue This Year
- MFIN N/A
- AARD N/A
- Revenue Next Year
- MFIN $3.82
- AARD N/A
- P/E Ratio
- MFIN $5.83
- AARD N/A
- Revenue Growth
- MFIN 15.53
- AARD N/A
- 52 Week Low
- MFIN $7.71
- AARD $4.88
- 52 Week High
- MFIN $10.98
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- MFIN 55.04
- AARD 42.18
- Support Level
- MFIN $9.14
- AARD $8.82
- Resistance Level
- MFIN $9.65
- AARD $11.23
- Average True Range (ATR)
- MFIN 0.32
- AARD 0.83
- MACD
- MFIN 0.02
- AARD -0.01
- Stochastic Oscillator
- MFIN 87.24
- AARD 31.97
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.